title: The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts.
abstract: Fibrosis is part of airway remodelling observed in bronchial asthma and COPD. Pro-fibrotic activity of lung fibroblasts may be suppressed by β-adrenoceptor activation. We aimed, first, to characterise the expression pattern of β-adrenoceptor subtypes in human lung fibroblasts and, second, to probe β-adrenoceptor signalling with an emphasis on anti-fibrotic actions. Using reverse transcription PCR, messenger RNA (mRNA) encoding β(2)-adrenoceptors was detected in MRC-5, HEL-299 and primary human lung fibroblasts, whereas transcripts for β(1)- and β(3)-adrenoceptors were not found. Real-time measurement of dynamic mass redistribution in MRC-5 cells revealed β-agonist-induced G(s)-signalling. Proliferation of MRC-5 cells (determined by [(3)H]-thymidine incorporation) was significantly inhibited by β-agonists including the β(2)-selective agonist formoterol (-logIC(50), 10.2) and olodaterol (-logIC(50), 10.6). Formoterol's effect was insensitive to β(1)-antagonism (GCP 20712, 3 μM), but sensitive to β(2)-antagonism (ICI 118,551; apparent, pA (2), 9.6). Collagen synthesis in MRC-5 cells (determined by [(3)H]-proline incorporation) was inhibited by β-agonists including formoterol (-logIC(50), 10.0) and olodaterol (-logIC(50), 10.3) in a β(2)-blocker-sensitive manner. α-Smooth muscle actin, a marker of myo-fibroblast differentiation, was down-regulated at the mRNA and the protein level by about 50% following 24 and 48 h exposure to 1 nM formoterol, a maximally active concentration. In conclusion, human lung fibroblasts exclusively express β(2)-adrenoceptors and these mediate inhibition of various markers of pro-fibrotic cellular activity. Under clinical conditions, anti-fibrotic actions may accompany the therapeutic effect of long-term β(2)-agonist treatment of bronchial asthma and COPD.
authors: Institute of Pharmacology & Toxicology, University of Bonn, Bonn, Germany.
authors: F
authors: F
authors: Lamyel
authors: M
authors: M
authors: Warnken-Uhlich
authors: W K
authors: WK
authors: Seemann
authors: K
authors: K
authors: Mohr
authors: E
authors: E
authors: Kostenis
authors: A S
authors: AS
authors: Ahmedat
authors: M
authors: M
authors: Smit
authors: R
authors: R
authors: Gosens
authors: H
authors: H
authors: Meurs
authors: A
authors: A
authors: Miller-Larsson
authors: Kurt
authors: K
authors: Racké
references: Trends Biochem Sci. 2006 Dec;31(12):680-6
references: 17084085
references: Proc Am Thorac Soc. 2004;1(3):176-83
references: 16113432
references: Br J Pharmacol. 2011 Oct;164(3):958-69
references: 21426315
references: Drug Discov Today. 2007 Jun;12(11-12):472-8
references: 17532532
references: Int Immunol. 2005 Nov;17(11):1473-81
references: 16210331
references: J Biol Chem. 2009 Jan 9;284(2):1324-36
references: 19010788
references: Science. 1998 Dec 18;282(5397):2275-9
references: 9856955
references: Am J Respir Cell Mol Biol. 2006 Jan;34(1):92-100
references: 16166747
references: Naunyn Schmiedebergs Arch Pharmacol. 2008 Dec;378(6):617-30
references: 18648773
references: Cardiovasc Drugs Ther. 1999 Apr;13(2):123-6
references: 10372227
references: Biochemistry. 1971 Mar 16;10(6):988-94
references: 4323854
references: J Biol Chem. 1978 May 25;253(10):3391-4
references: 206541
references: Respir Med. 2005 Apr;99(4):384-95
references: 15763443
references: Nature. 1998 Dec 3;396(6710):474-7
references: 9853756
references: Eur Respir J. 2000 Jan;15(1):68-74
references: 10678623
references: Nat Biotechnol. 2010 Sep;28(9):943-9
references: 20711173
references: Am J Med. 2004 Dec 20;117 Suppl 12A:24S-32S
references: 15693640
references: Curr Opin Allergy Clin Immunol. 2001 Feb;1(1):85-93
references: 11964675
references: Br J Pharmacol. 2011 Jan;162(1):193-209
references: 20804494
references: Naunyn Schmiedebergs Arch Pharmacol. 2008 Aug;378(2):193-201
references: 18270687
references: Pulm Pharmacol Ther. 2007;20(5):462-72
references: 16798034
references: Front Biosci. 2000 Aug 01;5:D678-93
references: 10922298
references: FASEB J. 2009 Feb;23(2):442-50
references: 18842964
references: Eur Respir J. 2008 Sep;32(3):555-62
references: 18480105
references: Cell Signal. 2008 Jan;20(1):10-20
references: 17716863
references: Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 2):S28-38
references: 11734464
references: Br J Pharmacol. 2005 Feb;144(3):317-22
references: 15655528
references: Lancet. 1989 Mar 11;1(8637):520-4
references: 2466184
references: N Engl J Med. 2004 Jun 24;350(26):2645-53
references: 15215480
references: Pulm Pharmacol. 1996 Jun;9(3):149-56
references: 8948511
references: Am J Physiol Lung Cell Mol Physiol. 2007 Feb;292(2):L405-13
references: 17028262
references: Am J Respir Cell Mol Biol. 2006 Dec;35(6):621-7
references: 16902194
references: J Pharmacol Exp Ther. 2010 Jul;334(1):53-62
references: 20371707
references: J Recept Signal Transduct Res. 2009;29(3-4):140-5
references: 19586284
references: JAMA. 2003 Nov 5;290(17):2301-12
references: 14600189
references: Pulm Pharmacol Ther. 2001;14(3):229-47
references: 11448150
references: Nature. 1995 Mar 16;374(6519):272-6
references: 7885448
references: Clin Respir J. 2010 May;4 Suppl 1:1-8
references: 20500603
references: Eur Respir J. 2001 Jul;18(1):139-45
references: 11510784
references: Mol Biotechnol. 2002 Oct;22(2):179-89
references: 12405265
references: J Cell Physiol. 2007 Jan;210(1):167-76
references: 17013807
references: Life Sci. 2007 May 30;80(24-25):2259-62
references: 17383686
references: Am J Physiol Cell Physiol. 2004 May;286(5):C1089-99
references: 15075208
references: Am J Respir Cell Mol Biol. 2008 Oct;39(4):482-9
references: 18421013
references: Lancet. 2004 Aug 21-27;364(9435):709-21
references: 15325838
references: J Allergy Clin Immunol. 2003 Feb;111(2):215-25; quiz 226
references: 12589337
references: Thorax. 2002 Mar;57(3):237-41
references: 11867828
references: Am J Respir Cell Mol Biol. 1990 Nov;3(5):507-11
references: 2223105
references: Thorax. 2002 Apr;57(4):309-16
references: 11923548